A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Inclusion Criteria:

• Documented diagnosis of multiple myeloma (MM) according to International MyelomaWorking Group (IMWG) diagnostic criteria

• Measurable disease at screening as defined by any of the following: Serum monoclonalparaprotein (M-protein) level greater than or equal to (>=)1.0 gram per deciliter (g/dL) or urine M-protein level >=200 milligram (mg)/24 hours; or Light chain MM inwhom only measurable disease is by serum free light chain (FLC) levels: Serumimmunoglobin (Ig) free light chain >=10 milligrams per deciliter (mg/dL) andabnormal serum Ig kappa/lambda FLC ratio

• Eastern Cooperative Oncology Group Performance Status grade of 0 or 1

• Not considered for high-dose chemotherapy with Autologous Stem Cell Transplant (ASCT) due to: Ineligible due to advanced age; or Ineligible due to presence ofcomorbid condition(s) likely to have a negative impact on tolerability of high-dosechemotherapy with ASCT; or Deferral of high-dose chemotherapy with ASCT as initialtreatment

• A woman of childbearing potential (WOCBP) must have 2 negative highly sensitiveserum or urine pregnancy tests (beta-human chorionic gonadotropin) prior to startingBortezomib, Lenalidomide and Dexamethasone (VRd) and must agree to further testingduring the study.

• Clinical laboratory values meeting the following criteria during the screeningphase: hemoglobin greater than or equal to (>=) 8.0 g/dL (>=5 millimoles per liter [mmol/L]), recombinant human erythropoietin use is permitted; platelets >=75 *10^9/L; absolute lymphocyte count >=0.3 *10^9/L; absolute neutrophil count (ANC) >=1.0 ×10^9/L (prior growth factor support is permitted but must be without supportin the 7 days prior to the laboratory test); aspartate aminotransferase (AST) andalanine aminotransferase (ALT) less than or equal to (<=) 3.0 * upper limit ofnormal (ULN); estimated glomerular filtration rate >=40 milliliter per minute/1.73meter square (mL/min/1.73 m^2) based upon modified diet in renal disease formula (MDRD-4) calculation or a 24-hour urine collection; total bilirubin <=2.0 * ULN;except in participants with congenital hyperbilirubinemia, such as Gilbert syndrome (in which case direct bilirubin <=2.0 * ULN is required)

Exclusion Criteria:

• Frailty index of >=2 according to Myeloma Geriatric Assessment score

• Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by theNational Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE)Version 5

• Known active, or prior history of central nervous system (CNS) involvement orclinical signs of meningeal involvement of MM

• Stroke or seizure within 6 months of signing Informed Consent Form (ICF)

• Seropositive for human immunodeficiency virus (HIV)

• Vaccinated with live, attenuated vaccine within 4 weeks prior to first dose of VRd

• Participant must not require continuous supplemental oxygen

• Hepatitis B infection

• Hepatitis C infection

• Prior treatment with chimeric antigen receptor T (CAR-T) therapy directed at anytarget

• Any therapy that is targeted to B-cell maturation antigen (BCMA)